Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Respistim is an immune-supporting dietary supplement developed by Muno-Vax, a health and wellness company based in Bulgaria. It is formulated as a complex containing Respivax, a polybacterial immunomodulator composed of killed bacterial lysates, alongside a blend of vitamins (A, C, D, E, and B-complex), minerals (manganese, copper, selenium), and antioxidants. The product is intended to enhance the body's natural defenses against respiratory infections, particularly during the autumn and winter seasons. It is marketed for adults and children over 9 years of age to reduce the frequency and severity of cold and flu symptoms. As a nutritional supplement, it is designed for long-term use during the cold season to support both non-specific and specific immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Respistim.